JPRN-jRCT2051200104已完成1 期
A Phase 1 Study of KK6483 in Healthy Male Volunteers
Yagi Michio0 个研究点目标入组 40 人开始时间: 2020年12月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 45age old(—)
- 性别
- Male
入选标准
- •1) Those who have provided voluntary written consent to participate in the study
- •2) Men aged >= 20 to < 45 years at the time of informed consent.
- •3) Those with BMI >= 18.5 to < 25.0 at the time of preliminary test
排除标准
- •1) Those with present illness requiring treatment
- •2) Those with a history of or current drug allergy
- •3) Those currently having respiratory disease, heart disease, gastrointestinal disease, renal disease, or hepatic disease
- •4) Those with a history of or current psychiatric disease
- •5) Those currently having clinically significant orthostatic hypotension
- •6) Those who have had a bacterial, viral, fungal, or parasitic infection within 28 days prior to signing the informed consent
研究者
相似试验
进行中(未招募)
1 期
A Study of MK-6482 in Combination with Lenvatinib Versus Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma (MK-6482-011)MedDRA version: 20.0Level: LLTClassification code 10038409Term: Renal cell carcinoma NOSSystem Organ Class: 100000004864Renal cell carcinomaEUCTR2020-002075-35-ATMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc708
进行中(未招募)
1 期
A Study of MK-6482 in Combination with Lenvatinib Versus Cabozantinib for Second-line or Third-line Treatment in Participants With Advanced Renal Cell Carcinoma (MK-6482-011)MedDRA version: 20.0Level: LLTClassification code 10038409Term: Renal cell carcinoma NOSSystem Organ Class: 100000004864Renal cell carcinomaEUCTR2020-002075-35-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc708
进行中(未招募)
1 期
A Study of MK-6482 in Combination with Lenvatinib Versus Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma (MK-6482-011)Renal cell carcinomaMedDRA version: 20.0Level: LLTClassification code 10038409Term: Renal cell carcinoma NOSSystem Organ Class: 100000004864EUCTR2020-002075-35-GRMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc708
进行中(未招募)
1 期
A Study of MK-6482 in Combination with Lenvatinib Versus Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma (MK-6482-011)EUCTR2020-002075-35-BEMerck Sharp & Dohme LLC708
进行中(未招募)
1 期
A Study of MK-6482 in Combination with Lenvatinib Versus Cabozantinib for Second-line or Third-line Treatment in Participants With Advanced Renal Cell Carcinoma (MK-6482-011)MedDRA version: 20.0Level: LLTClassification code 10038409Term: Renal cell carcinoma NOSSystem Organ Class: 100000004864Renal cell carcinomaEUCTR2020-002075-35-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.708
